arrow
C

Côme Lepage

hopital paris saint-joseph
H指数:49
被引数:9,218

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Interpretable AIto predict anal cancer local failure at 3 years with the FFCD Anabase prospective multicentric cohort

可解释AI预测FFCD Anabase前瞻性多中心队列中3年肛门癌局部复发

2026-08-010
PRE
Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61—FUNGEMAX trial (France)

纳曲伊立替康/5-氟尿嘧啶与吉西他滨/阿帕他汀相比纳曲伊立替康/5-氟尿嘧啶与吉西他滨/阿帕他汀在一线转移性胰腺癌中的序贯交替方案:法国随机II期PRODIGE 61—FUNGEMAX试验结果

2026-05-290
OAAI
Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study

二氢嘧啶脱氢酶表型指导的氟嘧啶在胃肠道癌症中的剂量个体化:PRODIGE100-UCGI48-FUDOSE II期研究

2026-05-220
OAAI
Association between induced organ atrophy assessed by artificial intelligence-generated automatic segmentation and efficacy of bevacizumab in combination with chemotherapy in metastatic colorectal cancer

人工智能自动分割评估的诱导性器官萎缩与贝伐珠单抗联合化疗在转移性结直肠癌中的疗效关联

2025-11-180
OAAI
Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer

5年CT扫描和CEA随访对结直肠癌患者生存终点的影响

2025-09-170
PRE
The impact of cancer survivors' extra risk of noncancer mortality on net survival estimation

癌症幸存者非癌症死亡率额外风险对净生存估计的影响

2025-09-011
OAAI
Deep learning on histological slides accurately predicts Consensus Molecular Subtypes and spatial heterogeneity in colon cancer

基于组织学切片的深度学习能够准确预测结直肠癌的共识分子亚型及空间异质性

2025-08-250
PRE
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)

Nal-IRI/LV5-FU 与紫杉醇作为转移性食管鳞状细胞癌患者二线治疗的比较(PRODIGE 62-FFCD 1701-OESIRI)

2025-08-220
OAAI
Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients – A post-hoc analysis of the PETACC 8 trial

合并用药对早期结直肠癌患者复发、生存和化疗耐受性的影响——PETACC 8试验的事后分析

2025-07-120
OA
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)

基于贝伐珠单抗的化疗,根据贝伐珠单抗药代动力学适应性调整,用于不可切除性转移性结直肠癌患者的一线治疗:一项双盲、多中心、随机III期临床试验研究(PHARBEVACOL试验)

2025-05-010
OAAI
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma

循环肿瘤DNA强烈预测化疗联合免疫检查点抑制剂在晚期胃食管腺癌患者中的疗效

2025-04-240
OA
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
2025-04-040
OAAI
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study

直肠腺癌伴同步转移患者的诱导三联化疗:一项AGEO-FFCD研究

2025-01-010
OAAI
Chemoradiotherapy versus radiotherapy alone in the management of early-stage anal squamous cell carcinoma: A comparative analysis of the French cohort FFCD-ANABASE
2025-01-010
PRE
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer
2024-11-121
OA